New Delhi: The upcoming India Pharma 2026 is set to spotlight India’s transition from volume-driven production to an innovation-led growth model in the pharmaceutical sector.
Industry leaders and policymakers are expected to use the platform to highlight the need for stronger research and development, advanced manufacturing, and greater global competitiveness. The focus is shifting from producing large quantities of generic medicines to developing high-value drugs, novel therapies, and cutting-edge technologies.
Experts believe this transition is crucial for India to strengthen its position in the global pharmaceutical landscape. While the country has long been known as a major supplier of affordable medicines, the next phase of growth will depend on investments in innovation, quality, and intellectual property.
The event will also provide an opportunity to discuss regulatory reforms, collaborations between industry and academia, and strategies to boost exports. Participants are likely to explore how emerging technologies and digital solutions can further enhance efficiency and innovation in the sector.
With growing global demand for advanced healthcare solutions, India Pharma 2026 is expected to serve as a key platform to shape the future direction of India’s pharmaceutical industry.
